Bangalore, India – May 15, 2026 – A recent commentary published in the journal Cancers has raised significant concerns regarding a meta-analysis that evaluated the oncological benefit of postoperative radiotherapy (PORT) for early-stage oral squamous cell carcinoma (OSCC) with perineural invasion (PNI). The authors of the commentary, led by Ganesh Datta Borewad from HCG Cancer Centre, Bangalore, argue that several methodological flaws and inconsistencies within the original meta-analysis may compromise the validity and clinical applicability of its conclusions.
The meta-analysis in question, authored by Rao et al., aimed to assess the impact of PORT on patients diagnosed with early-stage (T1/T2N0) OSCC who also exhibited perineural invasion. Perineural invasion is a recognized adverse pathological feature that can indicate a higher risk of recurrence and poorer prognosis in oral cancers. The decision to administer PORT in such cases is often complex, balancing the potential benefits of reducing recurrence against the known side effects of radiation therapy.
The commentary, published on May 9, 2026, with the article number 1520 in Cancers, highlights a series of critical issues within the Rao et al. meta-analysis, suggesting that these shortcomings necessitate a cautious interpretation of its findings. The authors contend that without addressing these points, the meta-analysis may not provide a reliable foundation for guiding treatment decisions for this specific patient population.
Key Criticisms and Methodological Concerns
The core of the critique centers on the heterogeneity of the studies included in the meta-analysis and the lack of precise definitions and reporting of crucial prognostic factors. The authors systematically dissect the original study, pointing out specific instances where the included research appears to deviate from the stated inclusion criteria or where data reporting is ambiguous.
1. Inadequate Characterization of Perineural Invasion (PNI)
A primary concern raised by the commentators is the insufficient detail regarding the characterization of perineural invasion across the studies analyzed by Rao et al. They note that only two of the included studies explicitly defined their criteria for identifying PNI. Crucially, critical prognostic variables such as whether the PNI was focal or multifocal, the caliber of the involved nerves, and the extent of its involvement were not consistently reported.
The commentary emphasizes that prior research has consistently demonstrated that multifocal PNI carries a significantly worse oncological outcome compared to unifocal PNI, even in early-stage OSCC. The absence of such detailed stratification in the meta-analysis means that risk adjustment for these important biological differences is lacking. This omission, the authors argue, could lead to an overestimation of the benefit of PORT in cases that might represent biologically lower-risk disease, thereby potentially misguiding clinical practice.
2. Inclusion of Studies with Conflicting Eligibility Criteria
The commentary identifies several studies within the meta-analysis that appear to contradict the stated inclusion criteria, thereby introducing potential confounders.
-
The Study by Holcomb et al.: This study reportedly included patients with pN0–N1 disease and also considered lymphovascular invasion (LVI) as a variable. The commentators point out that this appears to conflict with the meta-analysis’s stated aim of focusing on pN0 disease with PNI as the sole adverse feature. The inclusion of patients with nodal involvement or other high-risk pathological features like LVI could skew the survival outcomes attributed solely to PORT, diluting the specific effect being investigated.
-
The Study by Cheng et al.: This research involved patients who received postoperative chemoradiotherapy, not PORT alone. The commentators argue that the inclusion of systemic therapy, such as chemotherapy, introduces a significant confounder. This combination treatment can have a different impact on outcomes than radiotherapy alone, potentially inflating the perceived benefit of PORT.
-
The Study by Chen et al.: Patients in the study by Chen et al. were included based on the presence of PNI and/or LVI. Since LVI is an independent adverse prognostic factor, the commentary asserts that combining these variables directly conflicts with the meta-analysis’s premise of evaluating PNI as the sole adverse feature. This aggregation of risk factors could lead to inaccurate estimations of oncological outcomes.
3. Ambiguity and Potential Misclassification in Study Data
Further concerns are raised regarding the precise reporting and categorization of data within the included studies.
-
Ambiguity in the Study by Singareddy et al.: The original study by Singareddy et al. focused exclusively on carcinoma of the oral tongue. However, the meta-analysis’s Table 1 categorized the tumor site as "oral cavity," a broader classification. The commentators highlight that oral tongue cancers and other oral subsites have known prognostic and biological differences. This generalization could be misleading. Furthermore, this was the only study to provide detailed radiotherapy protocol information, underscoring a general lack of treatment heterogeneity reporting across the other studies.
-
Stage Misclassification in the Study by Nair et al.: The study by Nair et al. included patients who received adjuvant therapy based on depth of invasion (DOI) ≥10 mm and poor tumor differentiation. The commentators point out that these features are more consistent with T3 disease under contemporary staging systems rather than early-stage T1-T2 tumors. This potential stage misclassification could significantly impact the interpretation of results related to early-stage disease. Additionally, the definition of disease-free survival differed between the studies by Nair et al. and Cheng et al., further undermining outcome uniformity.
4. Numerical Discrepancy in Cohort Size
A significant and concerning discrepancy was noted in the reported cohort size. The abstract of the meta-analysis stated a total of 522 patients (281 receiving PORT and 241 not receiving PORT). However, the Results section and Table 1 of the same meta-analysis listed 248 patients in the no-PORT group. The commentators stress that clarification of this inconsistency is essential for maintaining data integrity and reader confidence in the study’s findings.
Historical Context and the Importance of PNI in OSCC Management
Oral squamous cell carcinoma (OSCC) remains a significant global health challenge, with advances in treatment and understanding continuously sought. Early detection and accurate prognostication are paramount in improving patient outcomes. Perineural invasion (PNI), the spread of cancer cells along nerves, is a well-established indicator of aggressive tumor behavior and a predictor of increased risk for local recurrence, regional metastasis, and distant spread.
Historically, the management of OSCC has evolved with a greater appreciation for the prognostic significance of various pathological features. For early-stage disease (T1/T2N0), where the primary tumor is small and there is no apparent spread to lymph nodes, the presence of PNI often prompts consideration of adjuvant therapy. However, the optimal modality and the definitive benefit of such therapy, particularly PORT, in the absence of other high-risk factors, have been subjects of ongoing debate and research.
The debate is further complicated by the significant morbidity associated with PORT, including xerostomia (dry mouth), dysphagia (difficulty swallowing), fibrosis, and the potential for secondary malignancies. Therefore, accurately identifying patients who will derive a meaningful benefit from PORT is crucial to avoid unnecessary toxicity. This underscores the importance of robust meta-analyses that meticulously review the evidence.
Supporting Data and Existing Literature
The commentary draws upon established literature to support its claims regarding the prognostic significance of PNI characteristics and other pathological factors. References are made to prior studies that have highlighted the differential impact of focal versus multifocal PNI, emphasizing that a nuanced understanding of PNI is essential for accurate risk stratification. The inclusion of studies with confounding factors like lymphovascular invasion or combined chemoradiotherapy, as pointed out, directly challenges the premise of isolating the effect of PORT on PNI alone.
The disparity in reported numbers for the no-PORT group, as highlighted in the commentary, is a factual inconsistency that undermines the statistical reliability of any conclusions drawn from the meta-analysis. This type of numerical discrepancy can arise from errors in data compilation, reporting, or analysis, and its presence necessitates a thorough re-examination of the data.
Official Responses and Implications
As of the publication of this commentary, there has been no official response from the authors of the original meta-analysis by Rao et al. The Cancers journal, as the publisher, facilitates peer review and scholarly discourse. This commentary represents a critical engagement with published research, a cornerstone of the scientific process.
The implications of these criticisms are significant for the clinical community. If the identified flaws are indeed substantial, the original meta-analysis may not provide the definitive guidance it intended for the management of early-stage OSCC with PNI. Clinicians relying on this meta-analysis to inform treatment decisions could potentially be misled, leading to either overtreatment or undertreatment of patients.
The commentary implicitly calls for a more rigorous approach to meta-analysis in this field. Future research should prioritize:
- Standardized Definitions: Clear and consistent definitions for pathological features, including PNI, are essential.
- Detailed Reporting: Studies included in meta-analyses should provide granular data on prognostic factors, such as the type and extent of PNI, nerve caliber, and the specific details of treatment regimens.
- Strict Adherence to Eligibility Criteria: Meta-analyses must meticulously adhere to their stated inclusion and exclusion criteria to avoid introducing confounders.
- Transparency in Data Presentation: Accurate and consistent reporting of cohort sizes and statistical data is paramount for the integrity of the research.
The authors of the commentary conclude by reiterating that while the meta-analysis addressed a pertinent clinical question, the identified issues necessitate cautious interpretation. They advocate for a refined analysis that either excludes studies with heterogeneous eligibility criteria and confounding factors or provides explicit justification for their inclusion. Such an approach, they argue, would further strengthen the robustness and clinical applicability of the conclusions drawn, thereby offering more reliable guidance for adjuvant treatment decisions in early-stage OSCC with isolated PNI.
This critical commentary serves as a vital reminder of the complexities involved in synthesizing scientific evidence and the importance of rigorous scrutiny in ensuring that research accurately informs clinical practice, ultimately benefiting patients facing challenging diagnoses like oral squamous cell carcinoma.
About the Author
